PluriStem Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by PluriStem Therapeutics Inc. on January 15, 2013. The registrant is a biopharmaceutical company incorporated in Nevada with principal executive offices in Haifa, Israel. The report addresses a specific regulatory milestone achieved on the date of filing.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the receipt of approval from the Paul-Ehrlich-Institute, the medical regulatory body for biological medicinal products in Germany. This approval permits the company to commence a Phase II clinical study using PLX-PAD cells in patients suffering from intermittent claudication.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or a discussion of risks and contingencies beyond the context of the regulatory approval. No unusual items were disclosed.
Key Facts for Investor Verification
- Regulatory approval was granted by the Paul-Ehrlich-Institute in Germany.
- The approved study is a Phase II clinical trial.
- The investigational product is PLX-PAD cells.
- The target patient population suffers from intermittent claudication.
- The approval was announced on January 15, 2013.